BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 19, 2009
View Archived Issues
Medivation Cleared to Begin Pivotal Prostate Cancer Trial
Well under way with pivotal trials of Alzheimer's disease drug Dimebon, Medivation Inc. is moving into late-stage development with another product, MDV3100, an androgen receptor antagonist, in prostate cancer. (BioWorld Today)
Read More
Battling FOB Bills Start March Through the House
Read More
Cost Cutting Continues: Cerus Latest Biotech to Slash Jobs
Read More
NewCo News: Auspex Focuses on Metabolism to Get More Bang from Drugs
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More